Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pharma Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN101270038B details a green synthesis of 4,4'-dihydroxybenzophenone using carbon tetrachloride and solid superacids, offering cost reduction and environmental compliance for pharmaceutical intermediates.
Novel chemo-enzymatic route for pseudouridine offers high purity and scalable production for mRNA vaccine manufacturers seeking reliable supply.
Novel zinc-mediated reduction route for Roxadustat intermediates. High purity, scalable, and cost-effective manufacturing solution for pharmaceutical supply chains.
Patent CN104193645A reveals efficient asymmetric synthesis. Delivers >99.5% ee. Ideal for Cilastatin production. Cost-effective supply chain solution for global buyers.
Patent CN115109759A reveals engineered carbonyl reductases achieving 600g/g S/C ratio. Discover cost-effective biocatalytic routes for chiral alcohol production.
Patent CN113234696B details a novel in vitro enzymatic route for crocetin from zeaxanthin, offering superior purity and scalable production for fine chemical manufacturing.
Patent CN108997355A reveals advanced recrystallization for Tofacitinib Citrate ensuring superior purity and yield for reliable pharmaceutical intermediates supplier partnerships.
Patent CN103159641A reveals low-cost lithiation route for tolvaptan intermediate ensuring high purity and supply chain stability for global pharmaceutical manufacturing.
Patent CN114196715A details a novel chemo-enzymatic method for pseudouridine using engineered glycosidase mutants, offering high conversion and simplified purification for mRNA vaccine supply chains.
Patent CN118374468B reveals mutant transaminase for high yield chiral amine intermediate production with improved stereoselectivity.
Patent CN105002234B reveals enzymatic cAMP synthesis. Offers high purity, cost reduction, and scalable supply for pharmaceutical intermediates manufacturing.
Patent CN106191150A details a co-immobilized enzymatic method for D-alanine. Achieves >98% purity with continuous 55-day operation, offering significant supply chain stability and cost reduction.
Novel Ni-catalyzed photochemical synthesis offers cost reduction and high enantioselectivity for pharmaceutical intermediates manufacturing.
Novel ionic liquid method for cyclopentanone ensures high yield and purity. Ideal for pharma and agrochemical supply chains seeking cost reduction.
Patent CN109943542A reveals enhanced ADH for Atazanavir. Lower cost, green synthesis, high purity pharmaceutical intermediates for global supply chains.
Patent CN110563760B details a green copper-catalyzed synthesis of phenyl thiodiphenyl phosphate, offering cost reduction and scalable manufacturing for agrochemical intermediates.
Enzymatic resolution patent CN112442523B enables high-purity chiral intermediate production with reduced costs and scalable supply chain reliability for global pharma.
Patent CN110922427A reveals TMSOTf-catalyzed route for sterically hindered phosphonites. Green, solvent-free process offers cost reduction in pharma intermediate manufacturing.
Novel organocatalytic route offers 99.8% ee. Green scalable process for pharma intermediates. Cost-effective supply chain solution for global buyers.
Patent CN111454918A details a novel OYE3-Mut mutant for >99% ee (R)-citronellal, offering cost-effective biocatalytic solutions for flavor and pharma intermediates.